Bellerophon Therapeutics is a US-based clinical-stage company working on products to treat cardiopulmonary diseases with a focus on pulmonary hypertension. Its flagship product INOpulse, a nitric oxide delivery platform, has treated various pulmonary hypertension conditions in the Phase 2 and Phase 3 clinical trials. The company was founded in 2009 and is headquartered in Warren, New Jersey, under the name Bellerophon Therapeutics, earlier known as Ikaria Development LLC.